A
Menu
First published September 17, 2026 Granted Aachen patent A – Human necessities

Binding proteins and uses thereof

Espacenet Family 95556875

Abstract

Novel nucleic acid compositions, vector systems, modified cells, and pharmaceutical compositions that encode or express T cell receptor components directed against KLK are provided herein. These novel components may be used to enhance an immune response in a subject diagnosed with prostate cancer. Associated methods for treating such subjects are also provided herein.

Inventors 2

  1. Mirjam, H.m. Heemskerk
  2. J.h., Frederik Falkenburg

Inventors are linked to an Aachen author when surname and first name match exactly one author.

Applicants

  • ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) GBS Leiden

Cited papers 31 in the database

Non-patent literature as cited (130)
  • - SCHOLTEN ET AL., CLIN. IMMUNOL., vol. 119, 2006, pages 135
  • - GOVERS ET AL., TRENDS MOL. MED., vol. 16, no. 2, 2010, pages 11
  • - SADELAIN ET AL., CANCER DISCOV, vol. 3, no. 4, 2013, pages 388
  • - HARRISKRANZ, TRENDS PHARMACOL. SCI., vol. 37, no. 3, 2016, pages 220
  • - STONE ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 63, no. 11, 2014, pages 1163
  • - BOWERMAN ET AL., MOL. IMMUNOL, vol. 5, no. 15, 2009, pages 3000
  • - BRENTJENS ET AL., CLIN. CANCER RES., vol. 73, 2007, pages 5426
  • - R MONJEZI ET AL., SLEEPING BEAUTY TRANSPOSITION FROM MINICIRCLE VECTORS, 2017
  • - LV COREN ET AL., BIOTECHNIQUES, 2015
  • - ROTH ET AL., NATURE, vol. 559, 2018, pages 405
  • - A.L. SZYMCZAK ET AL., NATURE BIOTECHNOLOGY, vol. 22, 2004, pages 589 - 594
  • - S JONES ET AL., HUMAN GENE THER, 2009
  • - RA WILLEMSEN ET AL., GENE THERAPY, 2000
  • - R MONJEZI ET AL., LEUKEMIA, 2017
  • - BS JONESLS LAMBF GOLDMANA DI STASI: "Improving the safety of cell therapy products by suicide gene transfer", FRONT PHARMACOL, vol. 5, 2014, pages 254
  • - MEYERS ET AL., CABIOS, vol. 4, 1989, pages 11 - 17
  • - AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1987, JOHN WILEY AND SONS, INC.
  • - COHEN ET AL., PROC. NATL. ACAD. SCI., vol. 69, 1972, pages 2110
  • - LUCHANSKY ET AL., MOL. MICROBIOL., vol. 2, 1988, pages 637 - 646
  • - HE, Q. ET AL., J HEMATOL ONCOL, vol. 12, 2019, pages 99
  • - EMILY HAN-CHUNG HSIUE ET AL., SCIENCE, vol. 371, no. 6533, 5 March 2021 (2021-03-05), pages 8697
  • - OKAMOTO S., CANCER RESEARCH, vol. 69, 2009, pages 9003 - 9011
  • - PROVASI E.GENOVESE P., NATURE MEDICINE MAY, vol. 18, no. 5, 2012, pages 807 - 15
  • - LOMBARDO A., NATURE BIOTECHNOLOGY, vol. 25, 2007, pages 1298 - 1306
  • - SOMMERMEYERUCKERT, J IMMUNOL, vol. 184, pages 6223 - 6231
  • - CONG, L.RAN, F.A.COX,D.LIN, S.BARRETTO, R.HABIB, N.HSU, P.D.WU, X.JIANG, W.MARRAFFINI, L.A., SCIENCE, vol. 339, no. 6121, 15 February 2013 (2013-02-15), pages 819 - 23
  • - JIANG W.BIKARD D.COX D.ZHANG FMARRAFFINI LA., NAT BIOTECHNOL MAR, vol. 31, no. 3, 2013, pages 233 - 9
  • - WANG H.YANG H.SHIVALILA CSDAWLATY MM.CHENG AW.ZHANG F.JAENISCH R., CELL, vol. 153, no. 4, 9 May 2013 (2013-05-09), pages 910 - 8
  • - KONERMANN S, BRIGHAM MD, TREVINO AE, HSU PD, HEIDENREICH M, CONG L, PIATT RJ, SCOTT DA, CHURCH GM, ZHANG F., NATURE, vol. 500, no. 7463, 22 August 2013 (2013-08-22), pages 472 - 6
  • - RAN, FA.HSU, PD.LIN, CY.GOOTENBERG, JS.KONERMANN, S.TREVINO, AE.SCOTT, DA.INOUE, A.MATOBA, S.ZHANG, Y., CELL, 28 August 2013 (2013-08-28)
  • - HSU, P.SCOTT, D.WEINSTEIN, J.RAN, FA.KONERMANN, S.AGARWALA, V.LI, Y.FINE, E.WU, X.SHALEM, O., NAT BIOTECHNOL, 2013
  • - RAN, FA.HSU, PD.WRIGHT, J.AGARWALA, V.SCOTT, DAZHANG, F., NATURE PROTOCOLS NOV, vol. 8, 2013, pages 2281 - 308
  • - SHALEM, O.SANJANA, NE.HARTENIAN, E.SHI, X.SCOTT, DA.MIKKELSON, T.HECKL, D.EBERT, BL.ROOT, DE.DOENCH, JG., SCIENCE, 12 December 2013 (2013-12-12)
  • - NISHIMASU, H.RAN, FA.HSU, PD.KONERMANN, S.SHEHATA, SIDOHMAE, N.ISHITANI, R.ZHANG, F.NUREKI, O., CELL, vol. 156, no. 5, 27 February 2014 (2014-02-27), pages 935 - 49
  • - WU X.SCOTT DA.KRIZ AJ.CHIU ACHSU PD.DADON DB.CHENG AW.TREVINO AE.KONERMANN S.CHEN S., NAT BIOTECHNOL., 20 April 2014 (2014-04-20)
  • - PIATT RJCHEN SZHOU YYIM MJSWIECH LKEMPTON HRDAHLMAN JEPARNAS OEISENHAURE TMJOVANOVIC M, CELL, vol. 159, no. 2, 2014, pages 440 - 455
  • - HSU PDLANDER ESZHANG F., CELL, vol. 157, no. 6, 5 June 2014 (2014-06-05), pages 1262 - 78
  • - WANG TWEI JJSABATINI DMLANDER ES, SCIENCE, vol. 343, no. 6166, 3 January 2014 (2014-01-03), pages 80 - 84
  • - DOENCH JGHARTENIAN EGRAHAM DBTOTHOVA ZHEGDE MSMITH ISULLENDER MEBERT BLXAVIER RJROOT DE., NAT BIOTECHNOL., vol. 32, no. 12, December 2014 (2014-12-01), pages 1262 - 7
  • - SWIECH LHEIDENREICH MBANERJEE AHABIB NLI YTROMBETTA JSUR MZHANG F., NAT BIOTECHNOL., vol. 33, no. 1, January 2015 (2015-01-01), pages 102 - 6
  • - KONERMANN SBRIGHAM MDTREVINO AEJOUNG JABUDAYYEH 00BARCENA CHSU PDHABIB NGOOTENBERG JSNISHIMASU H, NATURE, vol. 517, no. 7536, 29 January 2015 (2015-01-29), pages 583 - 8
  • - ZETSCHE BVOLZ SEZHANG F., NAT BIOTECHNOL., vol. 33, no. 2, February 2015 (2015-02-01), pages 139 - 42
  • - CHEN SSANJANA NEZHENG KSHALEM OLEE KSHI XSCOTT DASONG JPAN JQWEISSLEDER R, CELL, vol. 160, 12 March 2015 (2015-03-12), pages 1246 - 1260
  • - RAN FACONG LYAN WXSCOTT DAGOOTENBERG JSKRIZ AJZETSCHE BSHALEM OWU XMAKAROVA KS, NATURE, vol. 520, no. 7546, 9 April 2015 (2015-04-09), pages 186 - 91
  • - SHALEM ET AL.: "High-throughput functional genomics using CRISPR-Cas9", NATURE REVIEWS GENETICS, vol. 16, May 2015 (2015-05-01), pages 299 - 311, XP055207968, DOI: 10.1038/nrg3899
  • - XU ET AL.: "Sequence determinants of improved CRISPR sgRNA design", GENOME RESEARCH, vol. 25, August 2015 (2015-08-01), pages 1147 - 1157, XP055321186, DOI: 10.1101/gr.191452.115
  • - PARNAS ET AL.: "A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks", CELL, vol. 162, 30 July 2015 (2015-07-30), pages 675 - 686, XP029248090, DOI: 10.1016/j.cell.2015.06.059
  • - RAMANAN ET AL.: "CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus", SCIENTIFIC REPORTS, vol. 5, 2 June 2015 (2015-06-02), pages 10833
  • - NISHIMASU ET AL.: "Crystal Structure of Staphylococcus aureus Cas9", CELL, vol. 162, 27 August 2015 (2015-08-27), pages 1113 - 1126, XP055304450, DOI: 10.1016/j.cell.2015.08.007
  • - ZETSCHE ET AL.: "Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR- Cas System", CELL, vol. 163, 22 October 2015 (2015-10-22), pages 1 - 13
  • - JINEK ET AL., SCIENCE, vol. 337, 2012, pages 816 - 821
  • - BELFORT ET AL., NUCLEIC ACIDS RES, 1997
  • - NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
  • - ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
  • - ALTSCHUL ET AL., NUCL. ACIDS RES., vol. 25, 1997, pages 3389 - 3402
  • - LEFRANC M.-P.: "Unique database numbering system for immunogenetic analysis", IMMUNOLOGY TODAY, vol. 18, 1997, pages 509, XP004093509, DOI: 10.1016/S0167-5699(97)01163-8
  • - LEFRANC M.-P.: "The IMGT unique numbering for immunoglobulins, T cell Receptors and Ig-like domains", THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
  • - LEFRANC M.-P. ET AL.: "IMGT unique numbering for immunoglobulin and Tcell receptor variable domains and Ig superfamily V-like domains", DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
  • - LEFRANC M.-P. ET AL.: "IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains", DEV. COMP. IMMUNOL., vol. 29, 2005, pages 185 - 203, XP027722317
  • - SINGLETONSAINSBURY: "Dictionary of Microbiology and Molecular Biology", 1994, JOHN WILEY AND SONS
  • - HALEMARHAM: "The Harper Collins Dictionary of Biology", 1991, HARPER PERENNIAL
  • - "UniProt", Database accession no. UP000005640
  • - KARPANEN TOLWEUS J.: "T-cell receptor gene therapy - ready to go viral?", MOLECULAR ONCOLOGY, vol. 9, no. 10, 2015, pages 2019 - 2042, XP029341859, DOI: 10.1016/j.molonc.2015.10.006
  • - PARK JH, RIVIÈRE I, GONEN M, WANG X, SÉNÉCHAL B, CURRAN KJ, SAUTER C, WANG Y, SANTOMASSO B, MEAD E: "Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia ", N ENGL J MED, vol. 378, no. 5, 2018, pages 449 - 459, XP055849327, DOI: 10.1056/NEJMoa1709919
  • - MUNSHI NCANDERSON LDJR., SHAH NMADDURI DBERDEJA JLONIAL SRAJE NLIN YSIEGEL DORIOL A ET AL.: "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma", N ENGL J MED, vol. 384, no. 8, 2021, pages 705 - 716, XP055951668, DOI: 10.1056/NEJMoa2024850
  • - SIEGEL RLMILLER KDFUCHS HEJEMAL A.: "Cancer statistics", CA: A CANCER JOURNAL FOR CLINICIANS, vol. 72, no. 1, 2022, pages 7 - 33
  • - SANDHU SMOORE CMCHIONG EBELTRAN HBRISTOW RGWILLIAMS SG: "Prostate cancer", THE LANCET, vol. 398, no. 10305, 2021, pages 1075 - 1090
  • - FAY EKGRAFF JN.: "Immunotherapy in Prostate Cancer", CANCERS (BASEL), vol. 12, 2020, pages 7
  • - GRAF RPFISHER VWEBERPALS JGJOERUP OTIERNO MBHUANG RSPSAYEGH NLIN DLRASKINA KSCHROCK AB ET AL.: "Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumour Mutational Burden in Metastatic Castration-Resistant Prostate Cancer", JAMA NETWORK OPEN, vol. 5, no. 3, 2022, pages 225394
  • - MALEKI VAREKI S.: "High and low mutational burden tumours versus immunologically hot and cold tumours and response to immune checkpoint inhibitors", J IMMUNOTHER, vol. 6, no. 1, 2018, pages 157
  • - SCHEPISI GCURSANO MCCASADEI CMENNA CALTAVILLA ALOLLI CCERCHIONE CPAGANELLI GSANTINI DTONINI G ET AL.: "CAR-T cell therapy: a potential new strategy against prostate cancer", JOURNAL FOR IMMUNO THERAPY OF CANCER, vol. 7, no. 1, 2019, pages 258, XP055773435, DOI: 10.1186/s40425-019-0741-7
  • - NARAYAN VBARBER-ROTENBERG JSJUNG IYLACEY SFRECH AJDAVIS MMHWANG WTLAL PCARPENTER ELMAUDE SL ET AL.: "PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial", NATURE MEDICINE, vol. 28, no. 4, 2022, pages 724 - 734, XP037801527, DOI: 10.1038/s41591-022-01726-1
  • - DORFF TBNARAYAN VFORMAN SJZANG PDFRAIETTA JAJUNE CHHAAS NBPRICEMAN SJ.: "Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer", CLINICAL CANCER RESEARCH, vol. 28, no. 4, 2021, pages 576 - 584
  • - SADOVNIKOVA ESTAUSS HJ.: "Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumour immunotherapy", PROC NATL ACAD SCI, vol. 93, no. 23, 1996, pages 13114 - 13118, XP055101743, DOI: 10.1073/pnas.93.23.13114
  • - LEISEGANG MWILDE SSPRANGER SMILOSEVIC SFRANKENBERGER BUCKERT WSCHENDEL DJ.: "MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors", J CLIN INVEST, vol. 120, no. 11, 2010, pages 3869 - 3877, XP055103910, DOI: 10.1172/JCI43437
  • - JAHN LHOMBRINK PHASSAN CKESTER MGVAN DER STEEN DMHAGEDOORN RSFALKENBURG JHVAN VEELEN PAHEEMSKERK MH.: "Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b", BLOOD, vol. 125, no. 6, 2015, pages 949 - 958, XP055664245, DOI: 10.1182/blood-2014-07-587840
  • - MEEUWSEN MH, WOUTERS AK, JAHN L, HAGEDOORN RS, KESTER MGD, REMST DFG, MORTON LT, VAN DER STEEN DM, KWEEKEL C, DE RU AH: "A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy ", MOL THER, vol. 30, no. 2, 2022, pages 564 - 578, XP009539482, DOI: 10.1016/j.ymthe.2021.08.010
  • - LONSDALE JTHOMAS JSALVATORE MPHILLIPS RLO ESHAD SHASZ RWALTERS GGARCIA FYOUNG N ET AL.: "The Genotype-Tissue Expression (GTEx) project", NATURE GENETICS, vol. 45, no. 6, 2013, pages 580 - 585
  • - COLLADO-TORRES LNELLORE AKAMMERS KELLIS SETAUB MAHANSEN KDJAFFE AELANGMEAD BLEEK JT.: "Reproducible RNA-seq analysis using recount2", NAT BIOTECHNOL., vol. 35, no. 4, 2017, pages 319 - 321
  • - HICKS SCOKRAH KPAULSON JNQUACKENBUSH JIRIZARRY RABRAVO HC.: "Smooth quantile normalization", BIOSTATISTICS, vol. 19, no. 2, 2018, pages 185 - 198
  • - PAULSON JN, CHEN CY, LOPES-RAMOS CM, KUIJJER ML, PLATIG J, SONAWANE AR, FAGNY M, GLASS K, QUACKENBUSH J.: "Tissue-aware RNA-Seq processing and normalization for heterogeneous and sparse data ", BMC BIOINFORMATICS, vol. 18, no. 1, 2017, pages 437, XP021249659, DOI: 10.1186/s12859-017-1847-x
  • - RITCHIE MEPHIPSON BWU DHU YLAW CWSHI WSMYTH GK.: "limma powers differential expression analyses for RNA-sequencing and microarray studies", NUCLEIC ACIDS RES, vol. 43, no. 7, 2015, pages 47, XP093214494, DOI: 10.1093/nar/gkv007
  • - BUIJS JTRENTSCH CAVAN DER HORST GVAN OVERVELD PGMWETTERWALD ASCHWANINGER RHENRIQUEZ NVDIJKE PBOROVECKI FMARKWALDER R ET AL.: "BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 171, no. 3, 2007, pages 1047 - 1057, XP055707780, DOI: 10.2353/ajpath.2007.070168
  • - VAN DE MERBEL AFVAN DER HORST GVAN DER MARK MHBOTS STFVAN DEN WOLLENBERG DJMRIDDER CMASTUURMAN DAALDERS TERKENS-SCHULZ SVAN MONTFO: "Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models", CANCER GENE THERAPY, vol. 29, no. 6, 2022, pages 793 - 802, XP037893758, DOI: 10.1038/s41417-021-00360-2
  • - VAN AMERONGEN RAHAGEDOORN RSREMST DFGASSENDELFT DCVAN DER STEEN DMWOUTERS AKVAN DE MEENT MKESTER MGDRU AHGRIFFIOEN M ET AL.: "WT1-specific TCRs directed against newly identified peptides install antitumour reactivity against acute myeloid leukemia and ovarian carcinoma", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 10, no. 6, 2022, pages 004409, XP055968965, DOI: 10.1136/jitc-2021-004409
  • - VAN AMERONGEN RATUIT SWOUTERS AKVAN DE MEENT MSIEKMAN SLMEEUWSEN MHWACHSMANN TLAREMST DFGHAGEDOORN RSVAN DER STEEN DM ET AL.: "PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer", FRONTIERS IN, vol. 14, 2023
  • - HEEMSKERK MHHAGEDOORN RSVAN DER HOORN MAVAN DER VEKEN LTHOOGEBOOM MKESTER MGWILLEMZE RFALKENBURG JH.: "Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex", BLOOD, vol. 109, no. 1, 2007, pages 235 - 243, XP093032752, DOI: 10.1182/blood-2006-03-
  • - MATSUDA MONO RLYODA TENDO TIWASAKI MTOMIZAWA-MURASAWA MSAITO YKANEKO ASHIMIZU KYAMADA D ET AL.: "Human NK cell development in hIL-7 and hlL-15 knockin NOD/SCID/IL2rgKO mice", LIFE SCI ALLIANCE, vol. 2, 2019, pages 2
  • - CUNNINGHAM F, ALLEN JE, ALLEN J, ALVAREZ-JARRETA J, AMODE M R, ARMEAN IRINA M, AUSTINE-ORIMOLOYE O, AZOV ANDREY G, BARNES I, BENNE: "Ensembl 2022 ", NUCLEIC ACIDS RESEARCH, vol. 50, no. 1, 2021, pages 988 - 995
  • - UHLEN MKARLSSON MJZHONG WTEBANI APOU CMIKES JLAKSHMIKANTH TFORSSTROM BEDFORS FODEBERG J ET AL.: "A genome-wide transcriptomic analysis of protein-coding genes in human blood cells", SCIENCE, vol. 366, no. 6472, 2019, pages 9198
  • - ANDREATTA M, NIELSEN M.: "Gapped sequence alignment using artificial neural networks: application to the MHC class I system. ", BIOINFORMATICS, vol. 32, no. 4, 2016, pages 511 - 517, XP055566384, DOI: 10.1093/bioinformatics/btv639
  • - BUI HHSIDNEY JDINH KSOUTHWOOD SNEWMAN MJSETTE A.: "Predicting population coverage of T-cell epitope-based diagnostics and vaccines", BMC BIOINFORMATICS, vol. 7, 2006, pages 153, XP021013657, DOI: 10.1186/1471-2105-7-153
  • - SOTIROPOULOU GPAMPALAKIS GDIAMANDIS EP: "Functional roles of human kallikrein-related peptidases", J BIOL CHEM., vol. 284, no. 48, 2009, pages 32989 - 32994
  • - LAWRENCE MG, LAI J, CLEMENTS JA.: "Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus. ", ENDOCRINE REVIEWS, vol. 31, no. 4, 2010, pages 407 - 446
  • - SHAW JLDIAMANDIS EP: "Distribution of 15 human kallikreins in tissues and biological fluids", CLIN CHEM., vol. 53, no. 8, 2007, pages 1423 - 1432
  • - FUHRMAN-LUCK RALOESSNER DCLEMENTS JA.: "Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application", EJIFCC, vol. 25, no. 3, 2014, pages 269 - 281
  • - STEPHAN CJUNG KDIAMANDIS EPRITTENHOUSE HGLEIN MLOENING SA.: "Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer", UROLOGY, vol. 59, no. 1, 2002, pages 2 - 8
  • - AVGERIS MMAVRIDIS KSCORILAS A.: "Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance", BIOL CHEM, vol. 393, no. 5, 2012, pages 301 - 317
  • - KFOURY YBARYAWNO NSEVERE NMEI SGUSTAFSSON KHIRZ TBROUSE TSCADDEN EWIGOLKINA AAKOKKALIARIS K ET AL.: "Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment", CANCER CELL, vol. 39, no. 11, 2021, pages 1464 - 1478, XP086853479, DOI: 10.1016/j.ccell.2021.09.005
  • - QUEISSER A, HAGEDORN SA, BRAUN M, VOGEL W, DUENSING S, PERNER S.: " Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. ", MODERN PATHOLOGY, vol. 28, no. 1, 2015, pages 138 - 145
  • - ROUDIER MPTRUE LDHIGANO CSVESSELLE HELLIS WLANGE PVESSELLA RL.: "Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone", HUMAN PATHOLOGY, vol. 34, no. 7, 2003, pages 646 - 653
  • - AVGERIS MSTRAVODIMOS KSCORILAS A.: "Kallikrein-related peptidase 4 gene (KLK4) in prostate tumours: quantitative expression analysis and evaluation of its clinical significance", PROSTATE, vol. 71, no. 16, 2011, pages 1780 - 1789
  • - HERRALA AMPORVARI KSKYLLÖNEN APVIHKO PT: "Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumour tissue", CANCER, vol. 92, no. 12, 2001, pages 2975 - 2984, XP071173517, DOI: 10.1002/1097-0142(20011215)92:12<2975::AID-CNCR10113>3.0.CO;2-K
  • - LU XFONG K-WGRITSINA GWANG FBACA SCBREA LTBERCHUCK JESPISAK SROSS JMORRISSEY C ET AL.: "HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer", NATURE GENETICS., vol. 54, no. 5, 2022, pages 670 - 683
  • - NORRIS JDCHANG C-YWITTMANN BMKUNDER RSCUI HFAN DJOSEPH JDMCDONNELL DP.: "The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens", MOLECULAR CELL, vol. 36, no. 3, 2009, pages 405 - 416, XP028744127, DOI: 10.1016/j.molcel.2009.10.020
  • - YAO JCHEN YNGUYEN DTTHOMPSON ZJEROSHKIN AMNERLAKANTI NPATEL AKAGARWAL NTEER JKDHILLON J ET AL.: "The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers", SCIENTIFIC REPORTS, vol. 9, no. 1, 2019, pages 9715
  • - WEINER ABFAISAL FADAVICIONI EKARNES RJGRIEND DJVLOTAN TLSCHAEFFER EM.: "Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy", EUROPEAN UROLOGY ONCOLOGY, vol. 4, no. 6, 2021, pages 955 - 962
  • - WHITAKER HCWARREN AYEELES RKOTE-JARAI ZNEAL DE: "The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target", PROSTATE, vol. 70, no. 3, 2010, pages 333 - 340
  • - PRASSAS IEISSA APODA GDIAMANDIS EP: "Unleashing the therapeutic potential of human kallikrein-related serine proteases", NATURE REVIEWS DRUG DISCOVERY, vol. 14, no. 3, 2015, pages 183 - 202
  • - MORADI ASRINIVASAN SCLEMENTS JBATRA J.: "Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment", CANCER METASTASIS, vol. 38, no. 3, 2019, pages 333 - 346, XP036963962, DOI: 10.1007/s10555-019-09815-3
  • - AVGERIS MSCORILAS A.: "Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies", EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 20, no. 7, 2016, pages 801 - 818
  • - MADAN RAARLEN PMMOHEBTASH MHODGE JWGULLEY JL.: "Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer", EXPERT OPIN INVESTIG DRUGS, vol. 18, no. 7, 2009, pages 1001 - 1011, XP055886145, DOI: 10.1517/13543780902997928
  • - THOMAS-KASKEL AKWALLER CFSCHULTZE-SEEMANN WVEELKEN H.: "Immunotherapy with dendritic cells for prostate cancer", INT J CANCER, vol. 121, no. 3, 2007, pages 467 - 473, XP002675767, DOI: 10.1002/IJC.22859
  • - CORREALE PNIERODA CZAREMBA SZHU MSCHLOM JTSANG KYKONSTANTIN W.: "In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen", JNCI: JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 89, no. 4, 1997, pages 293 - 300, XP002039189, DOI: 10.1093/jnci/89.4.293
  • - CHAKRABORTY NGSTEVENS RLMEHROTRA SLASKA ETAXEL PSPORN JRSCHAUER PALBERTSEN PC.: "Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation", CANCER IMMUNOLOGY, IMMUNOTHERAPY., vol. 52, no. 8, 2003, pages 497 - 505, XP003004143, DOI: 10.1007/s00262-003-0377-8
  • - WILKINSON RWOODS KD'ROZARIO RPRUE RVARI FHARDY MYDONG YCLEMENTS JAHART DNJRADFORD KJ.: "Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients", CANCER IMMUNOLOGY,, vol. 61, no. 2, 2012, pages 169 - 179, XP035005853, DOI: 10.1007/s00262-011-1095-2
  • - HILLERDAL VNILSSON BCARLSSON BERIKSSON FESSAND M.: "T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells", PROC NATL ACAD SCI, vol. 109, no. 39, 2012, pages 15877 - 15881, XP093017249, DOI: 10.1073/pnas.1209042109
  • - MAO ZNESTERENKO PAMCLAUGHLIN JDENG WBURTON SOJO GCHENG DNOGUCHI MCHOUR WDELUCIA DCFINTON KA ET AL.: "Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 119, no. 31, 2022, pages 2203410119, XP093050356
  • - KORENCHUK SLEHR JEMCLEAN LLEE YGWHITNEY SVESSELLA RLIN DLPIENTA KJ.: "VCaP, a cell-based model system of human prostate cancer", IN VIVO, vol. 15, no. 2, 2001, pages 163 - 168, XP009539383
  • - SRAMKOSKI RMPRETLOW TG, 2NDGIACONIA JMPRETLOW TPSCHWARTZ SSY MSMARENGO SRRHIM JSZHANG DJACOBBERGER JW.: "A new human prostate carcinoma cell line, 22Rv1", IN VITRO CELL DEV BIOL ANIM, vol. 35, no. 7, 1999, pages 403 - 409
  • - THALMANN GNSIKES RAWU TTDEGEORGES ACHANG SMOZEN MPATHAK SCHUNG LW.: "LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis", PROSTATE, vol. 44, no. 2, July 2000 (2000-07-01), pages 91 - 103
  • - NATIONAL CANCER INSTITUTE, Retrieved from the Internet <URL:https://www.cancer.gov/tcga>
  • - WAARD AAVERKERK THOEFAKKER KVAN DER STEEN DMJONGSMA MLMBLISS SRU AHVAN VEELEN PAGRIFFIOEN MHEEMSKERK MHM ET AL.: "Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens", BIORXIV
  • - BURROWS SRKIENZLE NWINTERHALTER ABHARADWAJ MALTMAN JDBROOKS A.: "PeptideMHC class I tetrameric complexes display exquisite ligand specificity", J IMMUNOL., vol. 165, no. 11, 2000, pages 6229 - 6234
  • - VAN WETERING SVAN DER LINDEN ACVAN STERKENBURG MABOER WIKUIJPERS ALSCHALKWIJK JHIEMSTRA PS.: "Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins", AM J PHYSIOL LUNG CELL MOL PHYSIOL., vol. 278, no. 1, 2000, pages 51 - 58, XP002228134
  • - NAUTA AJ, DE HAIJ S, BOTTAZZI B, MANTOVANI A, BORRIAS MC, ATEN J, RASTALDI MP, DAHA MR, VAN KOOTEN C, ROOS A.: "Human renal epithelial cells produce the long pentraxin PTX3", KIDNEY INT, vol. 67, no. 2, 2005, pages 543 - 553, XP002486448, DOI: 10.1111/j.1523-1755.2005.67111.x
  • - VAN BERGEN CAVAN LUXEMBURG-HEIJS SAWREEDE LCEEFTING MDEM BORNE PAVAN BALEN PHEEMSKERK MHMULDER ACLAAS FHNAVARRETE MA ET AL.: "Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response", J CLIN INVEST, vol. 127, no. 2, 2017, pages 517 - 529
  • - LINNEMANN CHEEMSKERK BKVISTBORG PKLUIN RJBOLOTIN DACHEN XBRESSER KNIEUWLAND MSCHOTTE RMICHELS S ET AL.: "High-throughput identification of antigen-specific TCRs by TCR gene capture", NATURE MEDICINE, vol. 19, no. 11, 2013, pages 1534 - 1541, XP055190765, DOI: 10.1038/nm.3359
  • - RAY WILKINSON ET AL: "Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 2, 27 August 2011 (2011-08-27), pages 169 - 179, XP035005853, ISSN: 1432-0851, DOI: 10.1007/S00262-011-1095-2
  • - VAN AMERONGEN ROSA ET AL: "TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer", CANCER IMMUNOLOGY RESEARCH, 19 May 2025 (2025-05-19), pages 1145 - 1159, XP093313037, Retrieved from the Internet <URL:https://aacrjournals.org/cancerimmunolres/article-pdf/13/8/1145/3635717/cir-24-0119.pdf> DOI: 10.1158/2326-6066.CIR-24-0119 * the whole document * * Results, Table 1, pages 1147-1148 *

Cited patents 14

US6410319B1 US7446191B2 US2010065818A1 US8822647B2 WO2014031687A1 US7514537B2 WO2016071758A1 WO2004106380A2 US2004202657A1 US6750325B1 US20240156961A1 WO2022132596A2 WO2017089772A1 US2023346885A1